CO6390117A2 - Regimen de dosificación para un agonista de los receptores de s1p - Google Patents
Regimen de dosificación para un agonista de los receptores de s1pInfo
- Publication number
- CO6390117A2 CO6390117A2 CO11079290A CO11079290A CO6390117A2 CO 6390117 A2 CO6390117 A2 CO 6390117A2 CO 11079290 A CO11079290 A CO 11079290A CO 11079290 A CO11079290 A CO 11079290A CO 6390117 A2 CO6390117 A2 CO 6390117A2
- Authority
- CO
- Colombia
- Prior art keywords
- dosage regime
- agonist
- receiver agonist
- receiver
- dosage
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición Farmacéutica que comprenden un modulador o agonista de los receptores de S1P, de fórmula I,los cuales se administran siguiendo un régimen de dosificación en donde, durante los días iniciales del tratamiento, la dosificación diaria es más baja que la dosificación diaria convencional.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13967208P | 2008-12-22 | 2008-12-22 | |
US21853009P | 2009-06-19 | 2009-06-19 | |
US24671509P | 2009-09-29 | 2009-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6390117A2 true CO6390117A2 (es) | 2012-02-29 |
Family
ID=41667217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11079290A CO6390117A2 (es) | 2008-12-22 | 2011-06-23 | Regimen de dosificación para un agonista de los receptores de s1p |
Country Status (40)
Country | Link |
---|---|
US (11) | US20100160259A1 (es) |
EP (7) | EP2379067B1 (es) |
JP (6) | JP2012513401A (es) |
KR (1) | KR101347919B1 (es) |
CN (1) | CN102264359A (es) |
AR (1) | AR074826A1 (es) |
AU (1) | AU2009330176C9 (es) |
BR (1) | BRPI0923500A2 (es) |
CA (1) | CA2747802C (es) |
CL (2) | CL2011001529A1 (es) |
CO (1) | CO6390117A2 (es) |
CR (1) | CR20110274A (es) |
CU (1) | CU20110136A7 (es) |
CY (4) | CY1116990T1 (es) |
DK (3) | DK3453387T3 (es) |
EA (1) | EA201100978A1 (es) |
EC (1) | ECSP11011222A (es) |
ES (3) | ES2760607T3 (es) |
FR (1) | FR20C1060I1 (es) |
HN (1) | HN2011001759A (es) |
HR (3) | HRP20151190T1 (es) |
HU (4) | HUE048717T4 (es) |
IL (3) | IL213170A0 (es) |
LT (3) | LT3453387T (es) |
MA (1) | MA32981B1 (es) |
ME (2) | ME03802B (es) |
MX (2) | MX2011006623A (es) |
NO (1) | NO2020038I1 (es) |
NZ (1) | NZ593065A (es) |
PE (1) | PE20120337A1 (es) |
PL (3) | PL3409274T3 (es) |
PT (3) | PT2379067E (es) |
RS (2) | RS60666B1 (es) |
SG (1) | SG171404A1 (es) |
SI (3) | SI2379067T1 (es) |
TN (1) | TN2011000272A1 (es) |
TW (1) | TW201028143A (es) |
UY (1) | UY32352A (es) |
WO (1) | WO2010075239A1 (es) |
ZA (2) | ZA201103863B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101718639B1 (ko) | 2008-03-17 | 2017-03-21 | 액테리온 파마슈티칼 리미티드 | 선별적 s1p₁ 수용체 작동약에 대한 투약 섭생 |
EP2379067B1 (en) | 2008-12-22 | 2015-09-02 | Novartis AG | Dosage regimen for fingolimod for the treatment of multiple sclerosis |
EP3047848A1 (en) | 2009-09-29 | 2016-07-27 | Novartis AG | Dosage regimen of an s1p receptor modulator |
US20110124605A1 (en) * | 2009-11-20 | 2011-05-26 | Shreeram Aradhye | Use of an S1P Receptor Agonist |
EP4148045A1 (en) | 2010-01-27 | 2023-03-15 | Arena Pharmaceuticals, Inc. | Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof |
CN102917698A (zh) * | 2010-05-06 | 2013-02-06 | 诺瓦提斯公司 | 二芳基硫醚衍生物的给药方案 |
EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
FR2968556B1 (fr) | 2010-12-13 | 2013-12-27 | Centre Nat Rech Scient | Inhibiteurs des infections a vih et leurs utilisations |
DK2675893T3 (en) * | 2011-02-18 | 2019-04-15 | Scripps Research Inst | Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate |
JO3177B1 (ar) | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
WO2012162392A1 (en) * | 2011-05-23 | 2012-11-29 | Timothy Hla | Endothelium protective materials and methods of use |
TW201320994A (zh) | 2011-10-11 | 2013-06-01 | Novartis Ag | 投藥療程 |
CA2895172C (en) | 2012-08-17 | 2020-08-18 | Actelion Pharmaceuticals Ltd | Process for the preparation of|(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one and intermediate used in said process |
EP2964249A1 (en) * | 2013-03-06 | 2016-01-13 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure |
WO2015053878A1 (en) | 2013-10-11 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same |
US10675254B2 (en) | 2013-10-11 | 2020-06-09 | Teikoku Seiyaku Co., Ltd. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
SG11201607894RA (en) * | 2014-04-10 | 2016-10-28 | Novartis Ag | S1p modulator immediate release dosage regimen |
KR20200013086A (ko) | 2014-12-11 | 2020-02-05 | 액테리온 파마슈티칼 리미티드 | 선택적 s1p1 수용체 효능제에 대한 투약 섭생 |
KR20230151072A (ko) | 2015-01-06 | 2023-10-31 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 상태의 치료 방법 |
CA2973540A1 (en) | 2015-02-26 | 2016-09-01 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
HUE060476T2 (hu) | 2015-06-22 | 2023-03-28 | Arena Pharm Inc | (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra |
US11478448B2 (en) | 2017-02-16 | 2022-10-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
EP3582772A1 (en) | 2017-02-16 | 2019-12-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
JP2023501217A (ja) | 2019-10-31 | 2023-01-18 | イドーシア ファーマシューティカルズ リミテッド | Cxcr7アンタゴニストのs1p1受容体調節剤との合剤 |
WO2021158848A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor agonist |
US11135197B2 (en) | 2020-02-07 | 2021-10-05 | Argentum Pharmaceuticals Llc | Dosage regimen of an S1P receptor modulator |
CN113332435B (zh) * | 2021-06-18 | 2022-10-18 | 广州中医药大学(广州中医药研究院) | 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604229A (en) | 1992-10-21 | 1997-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
EP1315735A4 (en) | 2000-08-31 | 2005-04-06 | Merck & Co Inc | Phosphate derivatives as immunoregulatory compounds |
NZ536513A (en) | 2002-05-16 | 2007-10-26 | Novartis Ag | Use of EDG receptor binding agents in cancer |
CA2539033C (en) * | 2003-09-12 | 2013-03-05 | Neuronova Ab | Treatment of disease or injury of the nervous system with fty720 |
US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
AU2005309378B2 (en) * | 2004-11-29 | 2010-02-11 | Novartis Ag | Dosage regimen of an S1P receptor agonist |
EP1688141A1 (en) * | 2005-01-31 | 2006-08-09 | elbion AG | The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome |
WO2006085316A2 (en) * | 2005-02-10 | 2006-08-17 | G.I. View Ltd. | Advancement techniques for gastrointestinal tool with guiding element |
HUE027696T2 (en) * | 2007-10-12 | 2016-10-28 | Novartis Ag | Preparations containing sphingosine-1-phosphate (S1P) receptor modulators |
KR101718639B1 (ko) | 2008-03-17 | 2017-03-21 | 액테리온 파마슈티칼 리미티드 | 선별적 s1p₁ 수용체 작동약에 대한 투약 섭생 |
EP2303250A1 (en) * | 2008-06-20 | 2011-04-06 | Novartis AG | Paediatric compositions for treating1 multiple sclerosis |
BRPI0923213A2 (pt) * | 2008-12-22 | 2016-01-26 | Novaris Ag | regime de dosagem de um agonista do receptor para s1p. |
EP2379067B1 (en) | 2008-12-22 | 2015-09-02 | Novartis AG | Dosage regimen for fingolimod for the treatment of multiple sclerosis |
-
2009
- 2009-12-21 EP EP09797234.3A patent/EP2379067B1/en not_active Revoked
- 2009-12-21 EP EP15158251.7A patent/EP2907511A1/en not_active Withdrawn
- 2009-12-21 HU HUE18179301A patent/HUE048717T4/hu unknown
- 2009-12-21 JP JP2011542521A patent/JP2012513401A/ja not_active Withdrawn
- 2009-12-21 BR BRPI0923500-0A patent/BRPI0923500A2/pt not_active Application Discontinuation
- 2009-12-21 EP EP18179301.9A patent/EP3409274B1/en active Active
- 2009-12-21 SI SI200931311T patent/SI2379067T1/sl unknown
- 2009-12-21 MX MX2011006623A patent/MX2011006623A/es unknown
- 2009-12-21 RS RS20200900A patent/RS60666B1/sr unknown
- 2009-12-21 PT PT97972343T patent/PT2379067E/pt unknown
- 2009-12-21 HU HUE09797234A patent/HUE026869T2/en unknown
- 2009-12-21 US US12/642,892 patent/US20100160259A1/en not_active Abandoned
- 2009-12-21 SI SI200932015T patent/SI3409274T1/sl unknown
- 2009-12-21 ME MEP-2020-156A patent/ME03802B/me unknown
- 2009-12-21 SG SG2011037629A patent/SG171404A1/en unknown
- 2009-12-21 PT PT182010629T patent/PT3453387T/pt unknown
- 2009-12-21 AU AU2009330176A patent/AU2009330176C9/en not_active Withdrawn - After Issue
- 2009-12-21 WO PCT/US2009/068888 patent/WO2010075239A1/en active Application Filing
- 2009-12-21 EA EA201100978A patent/EA201100978A1/ru unknown
- 2009-12-21 EP EP22187007.4A patent/EP4098256A1/en active Pending
- 2009-12-21 PL PL18179301T patent/PL3409274T3/pl unknown
- 2009-12-21 EP EP16182876.9A patent/EP3120844A1/en not_active Withdrawn
- 2009-12-21 PE PE2011001265A patent/PE20120337A1/es not_active Application Discontinuation
- 2009-12-21 PT PT181793019T patent/PT3409274T/pt unknown
- 2009-12-21 KR KR1020117017073A patent/KR101347919B1/ko active IP Right Grant
- 2009-12-21 CA CA2747802A patent/CA2747802C/en active Active
- 2009-12-21 DK DK18201062.9T patent/DK3453387T3/da active
- 2009-12-21 HU HUE18201062A patent/HUE052048T2/hu unknown
- 2009-12-21 ES ES18179301T patent/ES2760607T3/es active Active
- 2009-12-21 PL PL09797234T patent/PL2379067T3/pl unknown
- 2009-12-21 UY UY0001032352A patent/UY32352A/es not_active Application Discontinuation
- 2009-12-21 EP EP20160225.7A patent/EP3677260A1/en active Pending
- 2009-12-21 AR ARP090105010A patent/AR074826A1/es not_active Application Discontinuation
- 2009-12-21 ES ES09797234.3T patent/ES2552823T3/es active Active
- 2009-12-21 RS RS20191546A patent/RS59857B1/sr unknown
- 2009-12-21 TW TW098143960A patent/TW201028143A/zh unknown
- 2009-12-21 LT LTEP18201062.9T patent/LT3453387T/lt unknown
- 2009-12-21 DK DK18179301.9T patent/DK3409274T3/da active
- 2009-12-21 PL PL18201062T patent/PL3453387T3/pl unknown
- 2009-12-21 SI SI200932080T patent/SI3453387T1/sl unknown
- 2009-12-21 LT LTEP18179301.9T patent/LT3409274T/lt unknown
- 2009-12-21 EP EP18201062.9A patent/EP3453387B1/en active Active
- 2009-12-21 US US13/141,552 patent/US20110257133A1/en not_active Abandoned
- 2009-12-21 NZ NZ593065A patent/NZ593065A/xx not_active IP Right Cessation
- 2009-12-21 MA MA34034A patent/MA32981B1/fr unknown
- 2009-12-21 ME MEP-2019-339A patent/ME03594B/me unknown
- 2009-12-21 DK DK09797234.3T patent/DK2379067T3/en active
- 2009-12-21 CN CN2009801518640A patent/CN102264359A/zh active Pending
- 2009-12-21 ES ES18201062T patent/ES2810823T3/es active Active
-
2011
- 2011-05-25 CR CR20110274A patent/CR20110274A/es not_active Application Discontinuation
- 2011-05-25 ZA ZA2011/03863A patent/ZA201103863B/en unknown
- 2011-05-26 TN TN2011000272A patent/TN2011000272A1/fr unknown
- 2011-05-26 IL IL213170A patent/IL213170A0/en unknown
- 2011-06-17 MX MX2021010759A patent/MX2021010759A/es unknown
- 2011-06-21 CL CL2011001529A patent/CL2011001529A1/es unknown
- 2011-06-22 EC EC2011011222A patent/ECSP11011222A/es unknown
- 2011-06-22 CU CU20110136A patent/CU20110136A7/es unknown
- 2011-06-22 HN HN2011001759A patent/HN2011001759A/es unknown
- 2011-06-23 CO CO11079290A patent/CO6390117A2/es not_active Application Discontinuation
-
2012
- 2012-08-06 ZA ZA2012/05942A patent/ZA201205942B/en unknown
-
2013
- 2013-05-31 CL CL2013001558A patent/CL2013001558A1/es unknown
- 2013-09-06 US US14/020,058 patent/US20140066657A1/en not_active Abandoned
-
2014
- 2014-01-31 US US14/169,660 patent/US20140148415A1/en not_active Abandoned
- 2014-04-10 JP JP2014080892A patent/JP2014144970A/ja not_active Withdrawn
-
2015
- 2015-10-14 JP JP2015202669A patent/JP2016135752A/ja not_active Withdrawn
- 2015-11-06 HR HRP20151190TT patent/HRP20151190T1/hr unknown
- 2015-11-30 CY CY20151101084T patent/CY1116990T1/el unknown
- 2015-12-02 US US14/956,855 patent/US20160081949A1/en not_active Abandoned
-
2016
- 2016-05-23 US US15/161,778 patent/US20160263061A1/en not_active Abandoned
-
2017
- 2017-03-06 JP JP2017041331A patent/JP2017141238A/ja not_active Withdrawn
- 2017-03-21 US US15/465,091 patent/US20170189353A1/en not_active Abandoned
-
2018
- 2018-06-11 US US16/005,137 patent/US20180289638A1/en not_active Abandoned
- 2018-11-26 US US16/199,905 patent/US20190091180A1/en not_active Abandoned
-
2019
- 2019-05-22 JP JP2019095899A patent/JP7329965B2/ja active Active
- 2019-12-02 HR HRP20192175TT patent/HRP20192175T1/hr unknown
- 2019-12-03 CY CY20191101264T patent/CY1122812T1/el unknown
-
2020
- 2020-05-05 US US16/867,293 patent/US20200330407A1/en not_active Abandoned
- 2020-05-18 IL IL274756A patent/IL274756A/en unknown
- 2020-07-27 HR HRP20201167TT patent/HRP20201167T1/hr unknown
- 2020-08-03 CY CY20201100712T patent/CY1123255T1/el unknown
- 2020-11-17 LT LTPA2020005C patent/LTPA2020005I1/lt unknown
- 2020-11-18 NO NO2020038C patent/NO2020038I1/no unknown
- 2020-11-19 CY CY2020036C patent/CY2020036I2/el unknown
- 2020-11-19 FR FR20C1060C patent/FR20C1060I1/fr active Active
- 2020-11-19 HU HUS2000046C patent/HUS2000046I1/hu unknown
- 2020-11-23 IL IL278914A patent/IL278914A/en unknown
-
2021
- 2021-09-20 US US17/479,649 patent/US20220142949A1/en active Pending
-
2022
- 2022-04-21 JP JP2022070231A patent/JP2022103194A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6390117A2 (es) | Regimen de dosificación para un agonista de los receptores de s1p | |
UY32350A (es) | Régimen de dosificación de un agonista de los receptores de s1p | |
EA201491607A1 (ru) | Модуляторы толлподобных рецепторов | |
SV2011004061A (es) | Aril-piridinas como inhibidores de sintasa de aldosterona | |
UY31863A (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
PE20150887A1 (es) | Compuestos de benceno sustituidos | |
CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
UY32156A (es) | Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones. | |
CO6690768A2 (es) | Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7 | |
SV2010003580A (es) | Agonistas novedosos de los receptores de glucocorticoides | |
UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
UY32853A (es) | Nuevos compuestos de oxadiazol | |
EA201001747A1 (ru) | Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств | |
CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. | |
CL2009002017A1 (es) | Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria. | |
CO6400188A2 (es) | Inhibidores de la fosfodiesterasa tipo iii (pdeiii) o agentes sensibilizantes al ca2+ para elt ratamiento de la cardiomiopatia hepertrófica | |
UY33348A (es) | Compuestos de furopiridina y usos de los mismos | |
CL2011000138A1 (es) | Uso de compuestos acido 1-{4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxiimino)-etil-2-etil-bencil}-azetidin-3-carboxilico para la preparacion de un medicamento para prevenir, inhibir o tratar una condicion inflamatoria seleccionada de polimiositis o dermatomiositis. | |
UY31646A1 (es) | Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico | |
UY32360A (es) | Compuestos de etanamina y métodos de utilización de los mismos 545 | |
CU20130155A7 (es) | Régimen de dosificación para un agonista de los receptores de s1p | |
CR11188A (es) | Compuestos de bencensulfonamida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 | |
CY1115622T1 (el) | Εστερες μετρονιδαζολης για αντιμετωπιση ροδοχρου ακμης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |